logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

2Seventy Bio, Inc.


USPTO Granted Patents = 24



Trademarks = 4

Forward Citations = 49

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Kevin Friedman (11 out of 21 patents)

silverMedal Jordan Jarjour (7 out of 23 patents)

bronzeMedal Richard Morgan (6 out of 14 patents)

4.  Kyle Havens (3 out of 9 patents)

5.  Jasdeep Mann (2 out of 6 patents)

6.  Joel Gay (2 out of 3 patents)

7.  Joy Zhang (2 out of 3 patents)

8.  Molly Reed Perkins (2 out of 5 patents)

9.  Alexander Astrakhan (2 out of 9 patents)

10.  Michael Certo (2 out of 5 patents)

11.  Wai-hang Leung (2 out of 6 patents)

12.  Anne-Rachel Krostag (1 out of 5 patents)

13.  Baeckseung Lee (1 out of 2 patents)

14.  Mark Pogson (1 out of 5 patents)

15.  Benjamin Boyerinas (1 out of 3 patents)


24 patents:

1. 12752006 - BCMA CHIMERIC ANTIGEN RECEPTORS (2026-10-06),
2. 12644099 - Methods for making T cell compositions (2026-06-02),
3. 12545746 - ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE (2026-02-10),
4. 12291722 - Methods for manufacturing adoptive cell therapies (2025-05-06),
5. 12247084 - Anti-BCMA CAR antibodies, conjugates, and methods of use (2025-03-11),
6. 12109234 - Anti-BCMA CAR T cell compositions (2024-10-08),
7. 12029784 - BCMA chimeric antigen receptors (2024-07-09),
8. 12006369 - BCMA chimeric antigen receptors (2024-06-11),
9. 11976116 - Salvage chimeric antigen receptor systems (2024-05-07),
10. 11952413 - Dimerizing agent regulated immunoreceptor complexes comprising interleukin receptor signaling domains (2024-04-09),
11. 11912746 - PD-1 homing endonuclease variants, compositions, and methods of use (2024-02-27),
12. 11779654 - PCSK9 endonuclease variants, compositions, and methods of use (2023-10-10),
13. 11732255 - CBLB endonuclease variants, compositions, and methods of use (2023-08-22),
14. 11654158 - TGFBeta signal convertor (2023-05-23),
15. 11633463 - BCMA chimeric antigen receptors (2023-04-25),
Company Overview
2Seventy Bio, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative cell therapies for cancer treatment. The organization focuses on harnessing the power of the immune system to create transformative therapies that target various malignancies. With a commitment to advancing the field of oncology, 2Seventy Bio is dedicated to pioneering research and technology that aims to improve patient outcomes and redefine cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

24 Patents

#114 in Cambridge, MA

#829 in Massachusetts

#13,872 in US

#26,628 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

2Seventy Bio, Inc.

Forward Citations = 49

21 inventors:

goldMedal Kevin Friedman (11 out of 21 patents)

silverMedal Jordan Jarjour (7 out of 23 patents)

bronzeMedal Richard Morgan (6 out of 14 patents)

4.  Kyle Havens (3 out of 9 patents)

5.  Jasdeep Mann (2 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: 2Seventy Bio, Inc.. Retrieved from https://idiyas.com/company/2seventy-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…